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Background: Surgical resection of malignant pleural mesothelioma is reported to
have up to an 80% rate of local recurrence. We performed a phase II trial of high-
dose hemithoracic radiation after complete resection to determine feasibility and to
estimate rates of local recurrence and survival.
Methods: Patients were eligible if they had a resectable tumor, as determined by
computed tomographic scanning, and adequate cardiopulmonary function for
extrapleural pneumonectomy or pleurectomy/decortication. After complete resec-
tion, patients received hemithoracic radiation (54 Gy) and then were followed up
with serial computed tomographic scanning.
Results: From 1995 to 1998, 88 patients (73 men and 15 women; median age, 62.5
years) were entered into the study. The operations performed included 62
extrapleural pneumonectomies (70%) and 5 pleurectomies/decortications; proce-
dures for exploration only were performed in 21 patients. Seven (7.9%) patients
died postoperatively. Adjuvant radiation administered to 57 patients (54 undergoing
extrapleural pneumonectomy and 3 undergoing pleurectomy/decortication) at a
median dose of 54 Gy was well tolerated (grade 0-2 fatigue, esophagitis), except for
one late esophageal fistula. The median survival was 33.8 months for stage I and II
tumors but only 10 months for stage III and IV tumors (P = .04). For the patients
undergoing extrapleural pneumonectomy, the sites of recurrence were locoregional
in 2, locoregional and distant in 5, and distant only in 30. 
Conclusion: Hemithoracic radiation after complete surgical resection at a dose not
previously reported is feasible. This approach dramatically reduces local recurrence
and is associated with prolonged survival for early-stage tumors. Stage III disease
has a high risk of early distant relapse and should be considered for trials of sys-
temic therapy added to this regimen of resection and radiation.
Malignant pleural mesothelioma (MPM) is an uncommon can-cer for which treatment options are limited. In its early stages,MPM remains localized to a single hemithorax, and therapeu-tic efforts have therefore focused on local treatment modali-ties, including surgical resection, radiation, intrapleuralchemotherapy, and photodynamic therapy. Although
extrapleural pneumonectomy (EPP) is associated with a lower risk of local recur-
rence than pleurectomy/decortication (P/D), surgical resection alone does not offer
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long-term local control in most patients.1,2 Previous experi-
ence with either adjuvant low-dose radiation or postoperative
intrapleural chemotherapy showed that these approaches
failed to prevent local recurrence.3-5 We sought to test the use
of high-dose hemithoracic radiation after complete surgical
resection of all gross tumors in an effort to achieve local con-
trol in early-stage MPM. We now report the results of this
phase II trial performed at Memorial Sloan-Kettering Cancer
Center (MSKCC).
Methods
Objectives
The objectives of this phase II trial for resectable MPM were as
follows: (1) to determine the feasibility of EPP combined with
high-dose, postoperative external-beam hemithoracic radiation; (2)
to determine the feasibility of combining P/D with intraoperative
radiation and postoperative external-beam radiation; (3) to deter-
mine the patterns of local and distant recurrence after this com-
bined modality treatment; and (4) to estimate overall survival after
this combined modality treatment.
Eligibility Criteria
Patients were eligible for this prospective phase II study if they had
potentially resectable, biopsy-proven MPM. The trial was approved
by the MSKCC Institutional Review Board, and informed consent
was obtained from all patients entered into the study.
The histologic diagnosis of MPM was confirmed in all cases by
means of immunohistochemistry, electron microscopy, or both. All
patients were evaluated with history and physical examination,
computed tomographic (CT) scanning of the chest and upper part
of the abdomen, laboratory data, pulmonary function testing, quan-
titative ventilation-perfusion scanning, echocardiography, and, if
clinically indicated, radionuclide stress testing. Additional scans to
determine whether distant metastases were present were per-
formed as clinically indicated. Patients were considered ineligible
for the study if they had another malignancy within the previous 5
years, had cardiopulmonary or renal insufficiency that made the
planned surgical resection prohibitively hazardous, or had a tumor
clearly involving the chest wall, abdomen, or distant organs, as
determined by means of examination or imaging studies.
Surgical Treatment Plan
All patients were to undergo an EPP unless contraindicated by
their preoperative pulmonary function or by the presence of con-
current medical problems that made the risk of pneumonectomy
prohibitive, in which case a P/D was performed.
The surgical technique used for both EPP and P/D has been
described previously.6 EPP was defined as an en bloc resection of
the entire pleura, lung, and diaphragm, with or without resection of
the pericardium. For left-sided resections, the diaphragm was
reconstructed with 2-mm thickness polytetrafluoroethylene,* and
for right-sided resections, reconstruction was with Dexon mesh
(Davis & Geck, Danbury, Conn). If resected, the pericardium was
also reconstructed with Dexon mesh. P/D included resection of the
parietal and mediastinal pleura and removal of involved areas of
the visceral pleura, without resection of the lung. Involved areas of
the pericardium and diaphragm were also resected and recon-
structed as necessary. At thoracotomy, a complete mediastinal
lymph node dissection was also to be performed.
Patients found to have an incompletely resectable or unre-
sectable tumor at thoracotomy because of unsuspected diffuse
involvement of the chest wall, transdiaphragmatic tumor extension
(T4 disease), or metastatic (M1) disease were removed from the
study and did not receive the planned adjuvant radiation. Final
pathologic staging was performed according to the International
Mesothelioma Interest Group staging system.7
Radiation Treatment Plan
For patients undergoing EPP, adjuvant external-beam radiation
started 3 to 5 weeks postoperatively. The target volume included
the entire hemithorax, the thoracotomy incision, and chest tube
incisions. A total of 54 Gy was delivered through anterior and pos-
terior fields in 30 daily fractions of 1.8 Gy by using 6-MV or
higher photons. The spinal cord was protected after 41.4 Gy.
Cerrobend blocks were used to limit the dose to the liver, heart, and
stomach when these organs were in the treatment field. Electrons
were used in the blocked regions to prevent underdosing to the
pleura and diaphragm.
Patients undergoing P/D received intraoperative radiation with
a previously described high-dose iridium applicator.8,9 A dose of
15 Gy was to be delivered to the mediastinum and diaphragm,
reducing this to 10 Gy over the heart and esophagus. For these
patients, external-beam radiation was also started 3 to 5 weeks
postoperatively. The dose administered was 45 to 54 Gy, and the
target volume included the perimeter of remaining lung tissue with
a 0.5- to 1.0-cm margin, the chest wall with a 1.0-cm margin, the
diaphragm, and the mediastinum.
Post-treatment Follow-up Plan
A physical examination and CT scan of the chest and upper
abdomen were performed 4 to 6 weeks after the end of external-
beam radiation and then every 3 to 4 months thereafter. In accord-
ance with previously reported criteria, local tumor progression was
defined as an increasing radiographic abnormality on serial CT
scans within or partially within the irradiated volume, provided
such an abnormality was not considered to be solely caused by
radiation pneumonitis.10,11 Tumor progression identified by CT or
other scans outside of the irradiated volume was considered to be
metastatic disease. Cytologic or histologic documentation of dis-
ease progression was required whenever technically feasible. All
patients were followed up until death or to the final date of analy-
sis for this study. Postmortem examinations were not routinely per-
formed because most patients who died of progressive disease
received terminal care locally in their communities, often far away
from MSKCC.
Statistical Methods
Survival probabilities were calculated by the product-limit method
of Kaplan and Meier. The prognostic significance of factors were
tested in a univariate model by the log-rank statistic for categoric
*Gore-Tex; registered trade mark of W. L. Gore & Associates, Inc,
Flagstaff, Ariz.
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covariates and by proportional hazards regression for continuous
covariates. Proportional hazards regression was used to test the
prognostic significance of factors in a multivariate model.12-14
Results
From 1993 to 1998, 103 patients were entered into the
study. As originally designed, the trial included intraopera-
tive radiation after both EPP and P/D. However, after 15
patients were entered into the study (EPP, 7 patients; P/D, 4
patients; unresectable, 4 patients), it was noted that the
intraoperative radiation unduly prolonged the length of the
operation (median, 9.2 hours; range, 1.0-13.4 hours) and
was associated with an unexpected frequency of infectious
complications in the patients undergoing EPP, including
empyemas. Therefore, with the approval of the institutional
review board, the trial was closed for the revision of the pro-
tocol, eliminating the intraoperative radiation for patients
undergoing EPP. The trial was then reopened for accrual.
The intraoperative radiation was retained for patients under-
going P/D because of the limitations of external-beam radi-
ation and the lower risk of infectious complications in these
cases. This report focuses on the 88 patients entered into the
revised protocol (MSKCC protocol #93-153A) between
1995 and 1998.
Patient Characteristics and Surgical Resection Data
The study schema and the numbers of patients in the study
at important time points are shown in Figure 1. The demo-
graphic information for these 88 patients, shown in Table 1,
reflects the usual sex, age, and tumor histology distribution
Figure 1. Study schema of MSKCC protocol #93-153A, with the numbers of patients noted at key study time points.
IORT, Intraoperative radiation therapy; EBRT, external beam radiation therapy.
TABLE 1. Demographic information for the 88 patients
entered into MSKCC protocol #93-153A
Male/female ratio 73:15
Median (range) age, y 62.5 (24-78)
Right/left ratio 55:33
Tumor histologic type
Epithelial 60
Mixed 20
Fibrosarcomatous 7
Desmoplastic 1
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of patients with MPM. Most patients were middle-aged or
older men, and epithelial tumors were the most common
histologic type.
Data related to surgical resection and tumor stage are
shown in Table 2. Of the 88 patients entered into the study,
21 did not have a completely resectable tumor at thoracot-
omy and were removed from the study; 62 patients had EPP,
and 5 underwent P/D. The median operative time was 4.1
hours (range, 1.0-10.3 hours), and the median blood loss
was 1050 mL (range, 40-5700 mL). There were 7 postoper-
ative deaths, all primarily related to pulmonary complica-
tions in patients who had undergone EPP. A total of 33
patients had at least one complication. The most common
complications (some patients had multiple complications)
were atrial arrhythmias (17 patients), respiratory failure (6
patients), pneumonia (5 patients), and empyema (5
patients).
Almost half of all patients had T1 or T2 tumors, and just
over 40% of tumors were N0 or N1. The N status was not
known for 18 patients who had unresectable or incompletely
resectable tumors, most frequently because of diffuse chest
wall invasion. However, because of either T3 or N2 status,
51% of all tumors were considered to be stage III, and only
22% were stage I or II.
Adjuvant Radiation Data
Of the 60 patients who survived and had a complete surgi-
cal resection, 3 did not receive adjuvant radiation because of
poor performance status. The remaining 57 patients (54 EPP
and 3 P/D) received a median dose of 54 Gy of radiation
(range, 20-64 Gy). Radiation-related complications are
shown in Table 3. In general, radiation was well tolerated,
with most toxicities being of grades 1 and 2. Grade 3 toxic-
ities included fatigue, esophagitis, nausea, and vomiting.
The most serious grade 4 toxicity was an esophagopleural
fistula, which developed several months after the comple-
tion of radiation and required an Eloesser flap for drainage.
Three years after EPP, the patient underwent substernal gas-
Figure 2. Overall survival of all extrapleural pneumonectomy
patients (n = 61).
Figure 3. Overall survival of extrapleural pneumonectomy patients
by histologic type.
TABLE 2. Surgical and staging data for the 88 patients
entered into MSKCC protocol #93-153A
Resection information
Exploration only 21
EPP 62
P/D 5
Operative mortality and morbidity
Mortality 7/88 (7.9%)
Morbidity (any type) 33/88 (37.5%)
T status
T1 7
T2 36
T3 25
T4 20
N status
N0 33
N1 4
N2 33
NX 18
M status
M0 85
M1 3
Stage categories
I 2
II 17
III 46
IV 23
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tric interposition to restore gastrointestinal continuity but
died postoperatively of respiratory failure. At death, the
patient remained clinically and pathologically free of dis-
ease. Review of the radiation doses and field did not reveal
any protocol violations or specific causes for the develop-
ment of the esophageal fistula.
Survival Estimates
Because just 5 patients underwent P/D, survival estimates
were performed only for the patients who underwent EPP
(Figures 2-6). One patient was lost to follow-up, and therefore
61 patients are included in these analyses. The median survival
for this entire group of patients was 17 months, and the over-
all survival at 3 years was 27% (Figure 2). For stage I and II
tumors, the median survival was 33.8 months, but survival was
only 10 months for stage III and IV tumors. The relationship
of several potential prognostic factors to overall survival was
examined by univariable analysis, and those results are shown
in Table 4. T and N status and stage all had a significant effect
on survival, whereas tumor histologic type (epithelial vs all
others) did not. None of these factors was significant in a mul-
tivariate analysis because histologic type is not significant uni-
variately, and the other 3 factors are highly associated with
each other. However, the analysis of prognostic factors in rela-
tion to survival should be interpreted cautiously because it was
not an end point of the study design and because of the rela-
tively small number of patients analyzed.
Sites of Relapse
The initial sites of relapse for the largest and most uniformly
treated group of patients, namely the 54 patients who under-
went both EPP and radiation, are shown in Table 5. A total
Figure 4. Overall survival of extrapleural pneumonectomy patients
by T status.
TABLE 3. Complications of adjuvant hemithoracic radiation described by Radiation Therapy Oncology Group grade compli-
cations
Grade
Type 0 1 2 3 4 LTF
WBC 42 6 1 0 0 1
Hemoglobin 37 11 1 0 0 0
PLT 43 5 1 0 0 1
Fatigue 5 14 27 6 2 0
Nausea 15 20 16 3 1 0
Vomiting 25 17 10 3 0 0
Esophagus 11 20 21 2 1 0
Lung 30 17 5 1 0 0
Heart 51 2 0 0 0 0
Skin 5 31 16 2 1 0
LTF, Life-threatening or fatal; WBC, white blood cell count; PLT, platelet count.
Figure 5. Overall survival of extrapleural pneumonectomy patients
by N status.
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of 7 (13%) patients had locoregional recurrence, but only 2
(3.7%) of these did not also have evidence of distant metas-
tases. Three (5.5% of all patients receiving radiation)
patients had locally recurrent disease in the region of the
previously resected pleura at the margins of the radiation
field. Distant metastases were the most common form of
relapse, with the peritoneum, contralateral pleura, and con-
tralateral lung being the most common sites.
Discussion
MPM is an uncommon malignancy, which was long consid-
ered uniformly fatal and untreatable. However, recent series
show that overall survival is much longer than previously
thought when MPM is diagnosed at an early stage.2,15-17
These series, which include larger numbers of patients than
were entered into this prospective clinical trial, all suggest
that tumor histologic type, T and N status, and stage signif-
icantly influence survival. Surgical resection and adjuvant
therapy, either radiation, chemotherapy, or both, seem to
have a beneficial effect on survival in selected patients.16,18
Despite some progress in treating MPM, including better
surgical selection and management, local control remains a
significant problem.18-20 Baldini and colleagues5 reported
that low-dose hemithoracic radiation (median, 31 Gy) failed
to provide local control after EPP, even when boost radia-
tion was given to sites of diseased surgical margins.
Adjuvant intrapleural chemotherapy and photodynamic
therapy have also failed to prevent local recurrence in most
patients after either P/D or EPP, even though they can be
administered with acceptable toxicity.2,4,21-23
At MSKCC, we had a large historical experience with
P/D and adjuvant radiation using an external beam with or
without intraoperative brachytherapy.24-27 A retrospective
review of that treatment strategy in 105 patients showed that
local recurrence was the predominant form of relapse and
that survival was poor, except in patients who had very
early-stage disease amenable to complete surgical resection
by means of P/D. Radiation pneumonitis and pericarditis
were also frequent complications.3 This experience led us to
explore other therapeutic approaches. Promising results
with intracavitary chemotherapy in ovarian cancer and in
patients with malignant pleural effusions led us to study
adjuvant intrapleural cisplatin-based chemotherapy in
patients who had MPM resected by means of P/D.28 That
Figure 6. Overall survival of extrapleural pneumonectomy patients
by stage.
TABLE 4. Univariate analysis of potential prognostic factors
on overall survival in patients who underwent EPP (n = 61)
No. of patients P value Hazard ratio (95% CI)
Histology
Epithelial 40 .57 1.20 
Other 21 (0.63-2.29)
N status
N0 24 .05 1.88 
Other 37 (N1 = 4; (0.97-3.63)
(N1 or N2) N2 = 33)
T status
T1 6 <.01 1.53 
T2 35 (T1 + T2 vs T3) (1.11-2.11)
T3 20
T4 0
Stage
I 2 .02 1.54 
II 17 (I + II vs III + IV) (1.07-2.22)
III 41
IV 1
TABLE 5. First sites of relapse in the 55 patients who under-
went EPP with postoperative radiation
Locoregional only 2
Distant only 30
Locoregional and distant 5
Locoregional
Pleural 3
Nodal 4
Distant
Peritoneal 17
Intralateral visceral 5
Contralateral pleural 13
Contralateral lung 8
Bone 7
Central nervous system 0
Other 5
Some patients had more than one site of recurrent disease at relapse.
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phase II trial showed a marked pharmacologic advantage for
the intrapleural administration of chemotherapy and a favor-
able median survival, but local recurrence was clearly the
most common form of relapse.4,29 The results of that study
led us to develop the trial reported here, with the underlying
hypothesis that complete surgical resection, preferably by
EPP, coupled with high-dose hemithoracic radiation was
feasible and might achieve local tumor control.
Our results show that adjuvant radiation, administered to
the entire hemithorax at a higher total dose than has been
reported previously, after EPP is feasible with acceptable
toxicity. This treatment strategy is associated with a very
low risk of local recurrence. These results differ strikingly
from those of our previous experience and those reported by
other centers.5,30-32 The few local recurrences in this study
appear to have been failures at the margins of the radiation
field, emphasizing the importance of treating the entire
hemithorax, including the diaphragm, costophrenic sulcus,
and ipsilateral half of the mediastinum. Careful and com-
plex radiation-treatment planning is required to avoid exces-
sive radiation to the stomach for left-sided tumors and to the
liver for right-sided tumors. It is also notable that the radia-
tion used in this study essentially eliminates the risk of
tumor recurrence in the chest wall that is commonly seen in
patients with MPM who have had thoracic incisions. In this
regard, our results are consistent with those of Boutin and
colleagues,33 who reported a randomized trial showing that
adjuvant radiation after thoracoscopy could prevent tumor
recurrence in the chest wall.
On the basis of the results of the study, we have adopted
EPP and high-dose hemithoracic radiation as our standard
approach to local tumor control in early-stage MPM. The
number of patients in this study treated with P/D, intraoper-
ative radiation, and postoperative external-beam radiation is
too small to estimate the toxicity and effectiveness of that
approach.
Our results clearly indicate that the greatest challenge
now is to prevent the development of metastatic disease,
especially in patients who have stage III tumors. The poor
survival of this group of patients, who represent the largest
subset in this study and in clinical practice generally,
remains the greatest concern. With recent improvements in
systemic therapy, it may be possible to add chemotherapy to
the treatment of patients with T3 or N2 disease.34 However,
previous experience with postoperative chemotherapy after
EPP does not suggest a marked survival benefit compared
with what we observed in this study for patients with stage
III tumors.15 Extrapolating from the experience with induc-
tion chemotherapy in stage III lung cancer, we hypothesize
that chemotherapy can be delivered more consistently and
effectively in the preoperative setting.35 Therefore, we have
begun to test such an approach in patients identified as hav-
ing T3 or N2 disease at diagnosis.
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